CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy

CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy

Triple-negative breast cancer (TNBC) is an aggressive subtype that constitutes 15–20% of breast cancer cases worldwide. Current therapies often evolve into chemoresistance and lead to treatment failure. About 77% of the TNBC lacks claudin-1 (CLDN1) expression, a major tight junction component, and t...

Full description

Bibliographic Details
Main Authors: Marine Lemesle, Marine Geoffroy, Fabien Alpy, Catherine-Laure Tomasetto, Sandra Kuntz, Isabelle Grillier-Vuissoz
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
breast cancer
TNBC
chemotherapy
CLDN1
sensitivity
apoptosis
Online Access:https://www.mdpi.com/2072-6694/14/20/5026

Internet

https://www.mdpi.com/2072-6694/14/20/5026

Similar Items